BACKGROUND AND PURPOSEAlternatively activated macrophages (AAMs) are important cells in the resolution of inflammation and tissue repair. We examined the impact of myofibroblasts, a vital cell in wound healing and tissue repair, on the development and function of AAMs.
EXPERIMENTAL APPROACHThe interaction between AAMs and myofibroblasts was tested using conditioned medium from murine dermal myofibroblasts and bone marrow-derived macrophages. AAMs were differentiated with IL-4 and IL-13.
KEY RESULTSConditioned medium from myofibroblasts enhanced the expression of AAM markers, arginase 1 and Ym1 (chitinase-3-like 3) and the spontaneous production of IL-10, while suppressing LPS-induced nitric oxide production. IL-6 from the myofibroblasts contributed to the amplification of the AAM phenotype; the selective COX-2 inhibitor, NS-398, significantly reduced the ability of myofibroblasts to promote an AAM phenotype. Pharmacological analyses indicated that myofibroblast-derived IL-6 enhanced arginase activity and spontaneous IL-10 output, while PGE 2 , via the EP 4 receptor, enhanced arginase expression and LPS-evoked IL-10 production. PGD 2 suppressed LPS-evoked nitric oxide via the DP 1 receptor. Reciprocally, conditioned medium from macrophages treated with IL-4 + IL-13 and myofibroblast conditioned medium components, but not macrophages given IL-4 + IL-13 only, reduced myofibroblast migration, the expression of COX-2, and the production of PGE 2 and PGD 2 .
CONCLUSIONS AND IMPLICATIONSThese findings define mechanisms by which myofibroblasts enhance an AAM phenotype, which can promote wound healing directly, and/or via feedback communication to the myofibroblast, subsequently down-regulating its capacity to promote AAM function. This is an important homeostatic regulatory pathway in wound healing that can also limit unwanted fibrosis.Abbreviations AAM, alternatively activated macrophage; ECM, extracellular matrix; MCM, macrophage conditioned medium; MFbCM, myofibroblast conditioned medium; M-CSF, macrophage-colony stimulating factor; SMA, smooth muscle actin BJP British Journal of Pharmacology